Table 2. Summary of clinical and radiological characteristics, treatment modalities, and outcomes in the present series.

Clinical characteristics	PXA	A-PXA	All
Total number of cases	17	2	19
Male, n (%)	8 (47%)	1 (50%)	9 (47%)
Age at diagnosis, median (range)	20 (7–68)	45 (16–74)	20 (7–74)
Initial symptoms, n (%)
Seizure	9 (53%)	1 (50%)	10 (53%)
Focal signs	7 (41%)	1 (50%)	8 (42%)
Other	1 (6%)	0	1 (5%)
Preoperative KPS, median (range)	90% (10–100)	80% (70–90)	90% (10–100)
Location, n (%)
Supratentorial	16 (94%)	2 (100%)	18 (95%)
Temporal lobe	9 (53%)	0	9 (47%)
Infratentorial	1 (6%)	0	1 (5%)
Tumor size*, median (range)	4.0 cm (2.0–8.0)	5.3 cm (3.5–7.0)	4.0 cm (2.0–8.0)
Peritumoral edema, n (%)
Mild to moderate	13 (76%)	2 (100%)	15 (79%)
Marked	4 (24%)	0	4 (21%)
Extent of resection, n (%)
Total resection	11 (65%)	0	11 (58%)
Subtotal resection	5 (29%)	2 (100%)	7 (37%)
Partial resection	1 (6%)	0	1 (5%)
Radiotherapy, n (%)	4 (24%)	2 (100%)	6 (32%)
Local radiotherapy	3 (18%)	1 (50%)	4 (21%)
Stereotactic radiotherapy	1 (6%)	0	1 (5%)
Combined	0	1 (50%)	1 (5%)
Chemotherapy, n (%)	2 (12%)	2 (100%)	4 (21%)
Combined with radiotherapy	1 (6%)	2 (100%)	3 (16%)
PFS rate, 5-year/10-year	63.5%/50.8%	50%/not reached	62.2%/49.8%
OS rate, 5-year/10-year	88.2%/88.2%	50%/not reached	84.2%/84.2%

^*The longest diameter determined on gadolinium-enhanced T1-weighted magnetic resonance imaging.

KPS: Karnofsky Performance Status, PFS: progression-free survival, OS: overall survival.